Canadian radioisotope developer ARTMS has received $300,000 Canadian ($237,590 U.S.) from Innovate BC to help develop the radioisotope zirconium-89 (Zr-89) for PET for patients who are eligible for immuno-oncology therapies.
This money, along with $600,000 Canadian ($475,000 U.S.) received from other resources, will be used to produce Zr-89 for the radiolabeling of molecular targeting ligands, such as antibodies, that are used in the noninvasive monitoring of the immune system by immuno-PET.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
